Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (2438)	3/30/2000 6:06:00 PM
From: Mike M	Respond to of 5582

On the contrary Hank, you have been very quick to intimate fraud at every opportunity. Before you fly off the handle, again, you had better take another look...Who said this was a zinc based product? Before you malign this company you need to check your facts. Furthermore, this is a classic reversal old buddy. Enjoy the ride!

To: Hank who wrote (2438)	3/30/2000 6:31:00 PM
From: DanZ	Read Replies (3) \| Respond to of 5582

There you go jumping to conclusions again, Hank. Where do you see in the press release that the Zicam allergy product is zinc based? The press release didn't say anything about the active ingredient. What are you going to tell the FTC and FDA when you contact them? You have no earthly idea what ingredients are in the product! And you call yourself a scientist? The scientists that I know put more thought into what they say before they shove their foot in their mouth. The important points about this product launch are as follows: The company already has distribution set up in 50,000 happy retail stores. According to the press release, they expect to put the allergy relief in all of them. "Initial interest from the retail chains is very high, based on the success of Zicam(TM) Cold Remedy. We anticipate Zicam(TM) Allergy Relief will achieve the same level of retail distribution as Zicam(TM) Cold Remedy." This should cause investors to revise their outlook for Q2 upwards. Based on the information in the press release, Q2 sales could be $8 million to $10 million because that's about what they did to fill the channel for Zicam cold remedy. "We have already received initial orders and anticipate beginning shipments in the next two weeks." The market size is nearly as large as the cough and cold category: "More than 35 million people suffer from seasonal allergic rhinitis, and they spend more than $2.5 billion dollars a year on allergy medications." This press release could spark a rally that takes the stock back to the mid 20 area. The stock is grossly undervalued because of a combination of factors that have already been discussed. I believe that this press release will alleviate concerns about sales next quarter and get the stock moving up again.